Molecular Templates Inc (OTCPK:MTEM)

$ 0.03 0.017 (130.77%) Market Cap: 198,000.00 Enterprise Value: -1.07 Mil PE Ratio: 0 PB Ratio: 0.03 GF Score: 0/100

Molecular Templates Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel Transcript
Mar 07, 2023
Molecular Templates Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Molecular Templates Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Molecular Templates Inc To Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting Transcript
Nov 11, 2022
Molecular Templates Inc To Discuss Unique Approach To Immuno-Oncology For Solid Tumors Call Transcript
Apr 13, 2022
Molecular Templates Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Molecular Templates Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Molecular Templates Inc To Discuss The Use of Egineer Toxin Bodies (EBTs) Transcript
Sep 29, 2020
Molecular Templates Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Molecular Templates Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 18, 2020
Molecular Templates Inc R&D Day Transcript
Nov 15, 2019
Molecular Templates Inc at UBS Global Healthcare Conference Transcript
May 20, 2019

Molecular Templates Inc To Discuss Unique Approach To Immuno-Oncology For Solid Tumors Call Transcript

Apr 13, 2022 / 12:00PM GMT

Release Date Price: $40.5 (-3.23%)

Transcript

Operator

Good morning, and welcome to the Molecular Templates webinar on a Unique Approach to Immuno-Oncology for Solid Tumors. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Molecular Templates' website following the conclusion of the event.

I'd now like to turn the call over to Dr. Eric Poma, Chief Executive Officer and Chief Scientific Officer of Molecular Templates. Please go ahead, Eric.

Eric E. Poma

Molecular Templates, Inc. - CEO, Chief Scientific Officer & Director

Thank you, Tara, and thank you to everyone joining today. We're very excited to be presenting some early, but I think very promising data on MT-6402, our differentiated approach to PD-L1. We're very fortunate here to have Dr. David Spigel, who is both the lead PI as well as discussing today. Dr. Spigel is the Chief Scientific Officer at Sarah Cannon.

And with that, I'll turn it over to Dr. Spigel.

David Spigel

Great. Thanks, Eric. Thanks, Tara. Good morning. I'm very honored

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.